Wen Chuan Zhou
Directeur Général chez MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
Fortune : 592 131 $ au 30/04/2024
Postes actifs de Wen Chuan Zhou
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Directeur/Membre du Conseil | 01/01/2009 | - |
| Directeur Général | 01/01/2009 | - | |
| GONGNIU GROUP CO.,LTD. | Directeur/Membre du Conseil | 20/05/2021 | - |
Shenzhen Wingor Bio-technology Co., Ltd.
 Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Wen Chuan Zhou
Formation de Wen Chuan Zhou
| The Chinese University of Hong Kong | Masters Business Admin |
| University of British Columbia | Graduate Degree |
Statistiques
Internationale
| Hong Kong | 3 |
| Chine | 3 |
| Canada | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Chief Executive Officer | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Consumer Services | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Distribution Services |
| GONGNIU GROUP CO.,LTD. | Producer Manufacturing |
| Entreprise privées | 1 |
|---|---|
Shenzhen Wingor Bio-technology Co., Ltd.
Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Commercial Services |
- Bourse
- Insiders
- Wen Chuan Zhou
- Expérience